Investigating how tumour microenvironment supports immune evasion
29 Oct 2024
Clinical Development
- How will targeting the tumor microenvironment open new avenues for drug development?
- What does the significant, yet transient, activity of immunotherapy for CNS tumors tell us about targeting this set of diseases?
- What discovery platforms and data sets will provide the best leads for developing immunotherapies that surmount negative tumor microenvironments?
- How can we layer new immunotherapies onto the successes seen with immune check-point blockade?
Industry Experts
